Ohe Y - Search Results

1

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Soria JC, et al. Among authors: ohe y. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. N Engl J Med. 2018. PMID: 29151359 Free article. Clinical Trial.

2

Phase II study of docetaxel and cisplatin administered as three consecutive weekly infusions for advanced non-small cell lung cancer.

Niho S, Ohe Y, Kakinuma R, Kubota K, Matsumoto T, Ohmatsu H, Goto K, Nishiwaki Y. Niho S, et al. Among authors: ohe y. Lung Cancer. 2002 Feb;35(2):209-14. doi: 10.1016/s0169-5002(01)00328-2. Lung Cancer. 2002. PMID: 11804695 Clinical Trial.

3

Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.

Kusaba H, Tamura T, Shimoyama T, Hotta K, Inoue A, Nokihara H, Ueda Y, Akiyama Y, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Kusaba H, et al. Among authors: ohe y. Jpn J Clin Oncol. 2002 Feb;32(2):43-7. doi: 10.1093/jjco/hyf013. Jpn J Clin Oncol. 2002. PMID: 11948227 Clinical Trial.

4

Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A).

Ohe Y, Ishizuka N, Tamura T, Sekine I, Nishiwaki Y, Saijo N; Japan Clinical Oncology Group. Ohe Y, et al. Cancer Sci. 2003 Aug;94(8):729-34. doi: 10.1111/j.1349-7006.2003.tb01510.x. Cancer Sci. 2003. PMID: 12901800 Free article.

5

Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.

Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Watanabe H, et al. Among authors: ohe y. Jpn J Clin Oncol. 2003 Dec;33(12):626-30. doi: 10.1093/jjco/hyg116. Jpn J Clin Oncol. 2003. PMID: 14769840

6

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Takano T, et al. Among authors: ohe y. Lung Cancer. 2004 Jul;45(1):93-104. doi: 10.1016/j.lungcan.2004.01.010. Lung Cancer. 2004. PMID: 15196739 Clinical Trial.

7

Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N. Sekine I, et al. Among authors: ohe y. Cancer Sci. 2004 Aug;95(8):691-5. doi: 10.1111/j.1349-7006.2004.tb03331.x. Cancer Sci. 2004. PMID: 15298734 Free article. Clinical Trial.

8

A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).

Ishikura S, Ohe Y, Nihei K, Kubota K, Kakinuma R, Ohmatsu H, Goto K, Niho S, Nishiwaki Y, Ogino T. Ishikura S, et al. Among authors: ohe y. Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1117-22. doi: 10.1016/j.ijrobp.2004.07.692. Int J Radiat Oncol Biol Phys. 2005. PMID: 15752891 Clinical Trial.

9

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Shibata T, Sakiyama T, Yoshida T, Tamura T. Takano T, et al. Among authors: ohe y. J Clin Oncol. 2005 Oct 1;23(28):6829-37. doi: 10.1200/JCO.2005.01.0793. Epub 2005 Jul 5. J Clin Oncol. 2005. PMID: 15998907

10

Erlotinib in lung cancer.

Takano T, Ohe Y. Takano T, et al. Among authors: ohe y. N Engl J Med. 2005 Oct 20;353(16):1739-41; author reply 1739-41. N Engl J Med. 2005. PMID: 16240472 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

701 results

Search Page